Synthetic inhibitors of hepatitis C virus NS3 protease
AssigneeSchering Corporation
InventorsRumin Zhang, Philip W. Mui, Patricia C. Weber
Life of this patent
Estimating the term…
Abstract
An inhibitor of the HCV NS3 protease. The inhibitor is a subsequence of a substrate of the NS3 protease or a subsequence of the NS4A cofactor. Another inhibitor of the present invention contains a subsequence of a substrate linked to a subsequences of the NS4A cofactor. In another embodiment the inhibitor is a bivalent inhibitor comprised of a subsequence, a mutated subsequence or a mutated full-length of a substrate of the NS3 protease linked to a subsequence, a mutated subsequence or a mutated full-length suquence of the HCV NS4A cofactor.
Claims7
A bivalent inhibitor of a hepatitis C NS3 protease comprised of a first peptide, a second peptide, and a linker, wherein
- said first peptide comprises a subsequence, a mutated subsequence or a mutated full-length sequence of a substrate of the hepatitis C NS3 protease which is not cleaved by the protease;
- said second peptide comprises a subsequence of a hepatitis C NS4A polypeptide selected from the group consisting of SEQ ID NO:
- 9, SEQ ID NO:
- 10, SEQ ID NO:
- 11, SEQ ID NO:
- 12, SEQ ID NO:
- 13, SEQ ID NO:
- 14 and SEQ ID NO:
- 15;
- and
- said linker comprises a chemical entity capable of forming a bond with said first peptide and said second peptide and is equivalent in length to a carbon chain having about 7-14 carbon atoms.
A monovalent inhibitor of a hepatitis C NS3 protease selected from the group consisting of SEQ ID NO:
- 9, SEQ ID NO:
- 10, SEQ ID NO:
- 11, SEQ ID NO:
- 12, SEQ ID NO:
- 13, SEQ ID NO:
- 14 and SEQ ID NO:
- 15.
Dependencies are inferred from the claim text.